<p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）在週二的一份研究報告中，由 StockNews.com 的股票研究人員將其評級從 “買入” 上調至 “強烈買入”。</p>
<ul>
<li>諾和諾德推出 Wegovy，成為三重威脅</li>
</ul>
<p>另外，Argus 將賽諾菲的目標股價從 55.00 美元上調至 60.00 美元，並在 7 月 26 日的一份報告中給予該股票 “買入” 評級。三位分析師對該股票進行了持有評級，兩位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標股價為 57.50 美元。</p>
<p><strong>查看我們關於賽諾菲的最新股票報告</strong></p>
<h2>賽諾菲股價表現</h2>
<ul>
<li>6 個購買輝瑞製藥股票的理由</li>
</ul>
<p>納斯達克 SNY 週二上漲 1.27 美元，收於 57.53 美元。該股交易量為 3,561,640 股，相比平均交易量 2,086,575 股有所增加。該公司的 50 天簡單移動平均線為 52.23 美元，200 天簡單移動平均線為 49.60 美元。該公司的速動比率為 0.65，流動比率為 1.00，負債權益比為 0.17。該公司的市值為 1,457.1 億美元，市盈率為 28.91，PEG 比為 1.60，貝塔係數為 0.60。賽諾菲的 12 個月最低價為 42.63 美元，最高價為 57.92 美元。</p>
<p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）上次公佈季度財報是在 7 月 25 日星期四。該公司報告季度每股盈利為 0.93 美元，超過了 0.88 美元的共識預期 0.05 美元。該季度營收為 107.5 億美元，低於分析師預期的 168.6 億美元。賽諾菲的淨資產回報率為 26.29%，淨利潤率為 9.60%。公司的營收同比增長了 7.8%。去年同期，公司每股盈利為 0.95 美元。研究分析師預計，賽諾菲本財年的每股盈利將達到 4.23 美元。</p>
<h2>機構投資者對賽諾菲的看法</h2>
<ul>
<li>投資的 20 個最佳醫療保健股票</li>
</ul>
<p>機構投資者最近增加或減少了他們在該股票中的持股。TCTC Holdings LLC 在第一季度將其在賽諾菲的持股增加了 28.0%。TCTC Holdings LLC 現在擁有 960 股該公司的股票，價值 47,000 美元，在上個季度購買了額外的 210 股。HB Wealth Management LLC 在第二季度將其在賽諾菲的持股增加了 3.7%。HB Wealth Management LLC 現在擁有 6,166 股該公司的股票，價值 29,900 美元，在上個季度購買了額外的 221 股。Wynn Capital LLC 在第一季度將其在賽諾菲的持股增加了 4.5%。Wynn Capital LLC 現在擁有 5,266 股該公司的股票，價值 25,600 美元，在上個季度購買了額外的 226 股。Insigneo Advisory Services LLC 在第二季度將其在賽諾菲的持股增加了 3.3%。Insigneo Advisory Services LLC 現在擁有 7,212 股該公司的股票，價值 37,100 美元，在上個季度購買了額外的 228 股。最後，Angeles Investment Advisors LLC 在第四季度將其在賽諾菲的持股增加了 2.1%。Angeles Investment Advisors LLC 現在擁有 12,029 股該公司的股票，價值 59,800 美元，在上個季度購買了額外的 244 股。該股的 10.04% 由機構投資者和對沖基金持有。</p>
<h2>關於賽諾菲（獲取免費報告）</h2>
<p>賽諾菲是一家醫療保健公司，從事在美國、歐洲和國際市場的治療解決方案的研究、開發、製造和營銷。它通過製藥、疫苗和消費者保健部門運營。該公司提供特殊護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；治療糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
<h2>精選故事</h2>
<ul>
<li>我們比賽諾菲更喜歡的五支股票</li>
<li>股市板塊：有多少種板塊？</li>
<li>內部人正在購買的 3 只小市值股票</li>
<li>什麼是 S&amp;P/TSX 指數？</li>
<li>分析師預測西部數據有巨大增長空間——不要錯過</li>
<li>投資的不同類型股票</li>
<li>今天市場上必須擁有的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 蒂姆·賽克斯的緊急交易警報：“立即採取行動”（來自蒂蒙西賽克斯）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4"/></p>
<h2>現在是否值得投資 1,000 美元購買賽諾菲股票？</h2>
<p>在考慮賽諾菲之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票... 而賽諾菲不在名單上。</p>
<p>雖然賽諾菲目前在分析師中有 “持有” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

賽諾菲

<p>賽諾菲被 StockNews.com 從"買入"調升至"強烈買入"。此外，Argus 調高了他們對該股票的目標價，目前分析師們普遍認為該股票為"中等買入"。交易量達到了超過 350 萬股，賽諾菲的市值約為 847.1 億美元。公司報告顯示，年度營收增長了 7.8%，並超出了本季盈利預期。機構投資者最近也在增加對該公司的持股</p>

<p>Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by equities researchers at StockNews.com from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Tuesday.</p>
<ul>
<li>Novo Nordisk Arms Wegovy to Be a Triple Threat</li>
</ul>
<div class="lb-trans"><p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）在週二的一份研究報告中，由 StockNews.com 的股票研究人員將其評級從 “買入” 上調至 “強烈買入”。</p>
<ul>
<li>諾和諾德推出 Wegovy，成為三重威脅</li>
</ul>
</div><p>Separately, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.50.</p>
<div class="lb-trans"><p>另外，Argus 將賽諾菲的目標股價從 55.00 美元上調至 60.00 美元，並在 7 月 26 日的一份報告中給予該股票 “買入” 評級。三位分析師對該股票進行了持有評級，兩位給出了買入評級，一位給出了強烈買入評級。根據 MarketBeat 的數據，該股票的共識評級為 “中等買入”，共識目標股價為 57.50 美元。</p>
</div><p><strong>View Our Latest Stock Report on Sanofi</strong></p>
<div class="lb-trans"><p><strong>查看我們關於賽諾菲的最新股票報告</strong></p>
</div><h2>Sanofi Price Performance</h2>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><h2>賽諾菲股價表現</h2>
<ul>
<li>6 個購買輝瑞製藥股票的理由</li>
</ul>
</div><p>NASDAQ SNY traded up $1.27 on Tuesday, reaching $57.53. 3,561,640 shares of the stock traded hands, compared to its average volume of 2,086,575. The firm's fifty day simple moving average is $52.23 and its 200 day simple moving average is $49.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $145.71 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 1.60 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.92.</p>
<div class="lb-trans"><p>納斯達克 SNY 週二上漲 1.27 美元，收於 57.53 美元。該股交易量為 3,561,640 股，相比平均交易量 2,086,575 股有所增加。該公司的 50 天簡單移動平均線為 52.23 美元，200 天簡單移動平均線為 49.60 美元。該公司的速動比率為 0.65，流動比率為 1.00，負債權益比為 0.17。該公司的市值為 1,457.1 億美元，市盈率為 28.91，PEG 比為 1.60，貝塔係數為 0.60。賽諾菲的 12 個月最低價為 42.63 美元，最高價為 57.92 美元。</p>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company's revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.95 EPS. As a group, research analysts predict that Sanofi will post 4.23 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>賽諾菲（納斯達克股票代碼：SNY - 獲取免費報告）上次公佈季度財報是在 7 月 25 日星期四。該公司報告季度每股盈利為 0.93 美元，超過了 0.88 美元的共識預期 0.05 美元。該季度營收為 107.5 億美元，低於分析師預期的 168.6 億美元。賽諾菲的淨資產回報率為 26.29%，淨利潤率為 9.60%。公司的營收同比增長了 7.8%。去年同期，公司每股盈利為 0.95 美元。研究分析師預計，賽諾菲本財年的每股盈利將達到 4.23 美元。</p>
</div><h2>Institutional Investors Weigh In On Sanofi</h2>
<ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><h2>機構投資者對賽諾菲的看法</h2>
<ul>
<li>投資的 20 個最佳醫療保健股票</li>
</ul>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. TCTC Holdings LLC raised its position in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company's stock worth $47,000 after purchasing an additional 210 shares during the last quarter. HB Wealth Management LLC increased its position in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after buying an additional 221 shares in the last quarter. Wynn Capital LLC increased its position in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock valued at $256,000 after buying an additional 226 shares in the last quarter. Insigneo Advisory Services LLC increased its position in shares of Sanofi by 3.3% in the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock valued at $371,000 after buying an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC increased its position in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock valued at $598,000 after buying an additional 244 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了他們在該股票中的持股。TCTC Holdings LLC 在第一季度將其在賽諾菲的持股增加了 28.0%。TCTC Holdings LLC 現在擁有 960 股該公司的股票，價值 47,000 美元，在上個季度購買了額外的 210 股。HB Wealth Management LLC 在第二季度將其在賽諾菲的持股增加了 3.7%。HB Wealth Management LLC 現在擁有 6,166 股該公司的股票，價值 29,900 美元，在上個季度購買了額外的 221 股。Wynn Capital LLC 在第一季度將其在賽諾菲的持股增加了 4.5%。Wynn Capital LLC 現在擁有 5,266 股該公司的股票，價值 25,600 美元，在上個季度購買了額外的 226 股。Insigneo Advisory Services LLC 在第二季度將其在賽諾菲的持股增加了 3.3%。Insigneo Advisory Services LLC 現在擁有 7,212 股該公司的股票，價值 37,100 美元，在上個季度購買了額外的 228 股。最後，Angeles Investment Advisors LLC 在第四季度將其在賽諾菲的持股增加了 2.1%。Angeles Investment Advisors LLC 現在擁有 12,029 股該公司的股票，價值 59,800 美元，在上個季度購買了額外的 244 股。該股的 10.04% 由機構投資者和對沖基金持有。</p>
</div><h2>About Sanofi (Get Free Report)</h2>
<div class="lb-trans"><h2>關於賽諾菲（獲取免費報告）</h2>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>賽諾菲是一家醫療保健公司，從事在美國、歐洲和國際市場的治療解決方案的研究、開發、製造和營銷。它通過製藥、疫苗和消費者保健部門運營。該公司提供特殊護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；治療糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Sanofi</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們比賽諾菲更喜歡的五支股票</li>
<li>股市板塊：有多少種板塊？</li>
<li>內部人正在購買的 3 只小市值股票</li>
<li>什麼是 S&amp;P/TSX 指數？</li>
<li>分析師預測西部數據有巨大增長空間——不要錯過</li>
<li>投資的不同類型股票</li>
<li>今天市場上必須擁有的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ 蒂姆·賽克斯的緊急交易警報：“立即採取行動”（來自蒂蒙西賽克斯）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9318&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sanofi right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買賽諾菲股票？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮賽諾菲之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票... 而賽諾菲不在名單上。</p>
</div><p>While Sanofi currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽諾菲目前在分析師中有 “持有” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

賽諾菲（NASDAQ:SNY）在 StockNews.com 被上調至強力買入評級